Skip to content

Pharmacy

Shopko files for Chapter 11 bankruptcy

Shopko files for Chapter 11 bankruptcy

Shopko Stores Operating Co. announced today that it has filed for Chapter 11 bankruptcy protection. The retailer reported that it would also be closing 38 stores as part of a reorganization process that was prompted by “excess debt and ongoing competitive pressures.

Aurobindo receives FDA approval for letrozole tablets

Aurobindo receives FDA approval for letrozole tablets

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for letrozole tablets USP, 2.5 mg. Aurobindo’s letrozole tablets are an AB-rated generic equivalent to the reference listed drug, Novartis’ Femara.

Camber Pharmaceuticals launches generic Albenza

Camber Pharmaceuticals launches generic Albenza

Camber Pharmaceuticals announces the addition of albendazole tablets to its growing portfolio of products. Albendazole tablets are the generic version of Albenza from Impax Labs and is used to treat infections of tapeworms or other parasites.

New Rx treatment option for adult acne

New Rx treatment option for adult acne

Acne, the common skin condition that occurs when hair follicles become plugged with oil and dead skin cells, is most often associated with the awkwardness of adolescence. However, it’s more common in adults, especially adult women, than most ­realize.

Takeda completes Shire acquisition

Takeda completes Shire acquisition

Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release. The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said.

NACDS urges members to submit DIR comments by January 25

NACDS urges members to submit DIR comments by January 25

Each NACDS member company has a powerful opportunity to submit official comments to the Centers for Medicare & Medicaid Services (CMS) in support of direct and indirect remuneration (DIR) fee reform concepts described in the agency’s proposed rule, “Modernizing Part D and Medicare Advantage to Lower